EUVIMEDEUVIMED entdecken
Crossref

The negative outlook: Long‐term follow up of ThyroSeq negative and low‐risk nodules

Raquel A Perry iD, Megan F Lee, Rachel C Jug iD, Rajesh C Dash, Daniel J Rocke, Xiaoyin Sara Jiang iD

Cancer Cytopathology · 2024

DOI: 10.1002/cncy.22875 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cytopathology, 2024. Verfasst von Raquel A Perry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Thyroid Nodule. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular testing of thyroid nodules is an essential tool to help risk stratify nodules with indeterminate cytology. Although ThyroSeq testing has been around for over a decade, there is a paucity of long‐term follow‐up data on cytologically indeterminate nodules that are determined to be molecularly negative or low‐risk. The objective of this study is to assess the outcomes of nodules with indeterminate cytology (Bethesda III or IV) and negative or low‐risk ThyroSeq results.

Methods

This is a single academic institution retrospective cohort study. Patients with at least one thyroid nodule sampled with fine‐needle aspiration who underwent ThyroSeq testing from 2012 to 2018 and had negative or low‐risk ThyroSeq results on a cytologically indeterminate sample ( n = 159 patients, 167 nodules) were included in the study. Outcomes include the false‐negative rate and negative predictive value of each test version, as well as follow‐up length for each nodule.

Results

There were 159 patients with a mean age of 58 years (7–84 years) included in this study; the majority were female (81.8%). The mean follow‐up was 4.0 years. Of 167 nodules, three were found to be malignant on resection (1.8%). The negative predictive value for the entire cohort was 98.2% and it was 89.3% for the surgical series.

Conclusion

ThyroSeq testing has good negative predictive value and can help risk stratify cytologically indeterminate nodules. Routine follow‐up allows for safe monitoring of nodules for features suggestive of malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NoduleAdolescentAdultAgedAged, 80 and overChildFemaleHumansMaleMiddle AgedYoung AdultBiopsy, Fine-NeedleCytodiagnosisFollow-Up StudiesPredictive Value of TestsRetrospective StudiesThyroid Neoplasms

Stichwörter der Autor:innen

cytologymolecular diagnostic techniquespathologythyroid neoplasmsthyroid nodule

Autor:innen und Institutionen

  • Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.
  • Department of Pathology, University of Cincinnati Medical Center, Cincinnati, Ohio, USA.
  • Department of Head and Neck Surgery and Communication Sciences, Duke University Health Systems, Durham, North Carolina, USA.

ORCID-Profile: Raquel A Perry, Rachel C Jug, Xiaoyin Sara Jiang

Zitieren

APA

Perry, R. A., Lee, M. F., Jug, R. C., Dash, R. C., Rocke, D. J., & Jiang, X. S. (2024). The negative outlook: Long‐term follow up of ThyroSeq negative and low‐risk nodules. Cancer Cytopathology. https://doi.org/10.1002/cncy.22875

Vancouver

Perry RA, Lee MF, Jug RC, Dash RC, Rocke DJ, Jiang XS. The negative outlook: Long‐term follow up of ThyroSeq negative and low‐risk nodules. Cancer Cytopathology. 2024. doi:10.1002/cncy.22875

BibTeX
@article{Perry2024,
  author = {Perry, Raquel A and Lee, Megan F and Jug, Rachel C and Dash, Rajesh C and Rocke, Daniel J and Jiang, Xiaoyin Sara},
  title = {The negative outlook: Long‐term follow up of ThyroSeq negative and low‐risk nodules},
  journal = {Cancer Cytopathology},
  year = {2024},
  doi = {10.1002/cncy.22875}
}
Kostenlos starten →